SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-004043
Filing Date
2023-01-09
Accepted
2023-01-09 06:05:33
Documents
12
Period of Report
2023-01-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d612899d8k.htm   iXBRL 8-K 25891
  Complete submission text file 0001193125-23-004043.txt   148886

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cbay-20230106.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20230106_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20230106_pre.xml EX-101.PRE 11260
6 EXTRACTED XBRL INSTANCE DOCUMENT d612899d8k_htm.xml XML 3353
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 23516408
SIC: 2834 Pharmaceutical Preparations